Site is currently under construction
On May 12, 2014, Telik announced that it had signed a definitive agreement to merge with MabVax Therapeutics, Inc. (“MabVax”), a private biotechnology company that shares Telik’s oncology focus, and on July 8, 2014, the parties completed the merger. The combined company is currently named Telik, Inc. is currently traded on the OTCQB under the symbol TELK. The company has filed a definitive proxy for a stockholders vote to complete the process of changing the name to MabVax Therapeutics Holdings Inc., complete a 1 for 5 reverse stock split to enable the company to meet the initial listing requirements for NASDAQ, and authorize additional shares. The stockholder vote is scheduled for August 20, 2014 and more information can be found by following this link
Like Telik, MabVax is focused on the clinical development of novel cancer therapies, with several anti-cancer drugs in late stage clinical testing. MabVax was founded in 2006 and is focused the discovery of and development of innovative vaccine and monoclonal antibody-based therapeutics for the diagnosis and treatment of cancer. MabVax has licensed its vaccine product portfolio from Memorial Sloan Kettering, an institution that has a long-standing relationship with Telik. MabVax has discovered a library of fully-human antibodies based on the immune response of patients vaccinated with the licensed vaccines. The merger now allows the two entities, which operate in the same space, to create synergies by enhancing the pipeline of the combined entity and creating a critical mass of cancer drug candidates and capabilities. In addition to Telik’s existing pre-merger programs, MabVax has two products in late Phase 2 clinical trials, with 35 patents and 7 patents pending.
Founded in 1988, Telik is a clinical stage drug development company focused on the discovery and development of small molecule drugs to treat cancer. The Company’s most advanced drug candidate is Telintra® for the treatment of myelodyplastic syndrome, followed by earlier stage compounds for the treatment of a variety of cancers. Historically, Telik’s business strategy has been to advance its drug product candidates through Phase 2 clinical studies, and to enter into partnership(s) with pharmaceutical or biotechnology companies to assist in the further development and commercialization of its product candidates. MabVax is in the early stages of evaluating the Telik programs and will determine which, if any, programs to move forward.